Mark C. McKenna - 03 Sep 2026 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Reporting relationship: Director
Issuer ticker: APGE
Reported as of: 03 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Sep 2026, 16:39:17 UTC
Prior SEC filing: 22 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Batters, as attorney-in-fact for Mark McKenna

Key filing fact

Mark C. McKenna filed Form 4 for Apogee Therapeutics, Inc. (APGE) on 03 Sep 2026.

Key facts

This page summarizes Mark C. McKenna's Form 4 filing for Apogee Therapeutics, Inc. (APGE).
5 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 03 Sep 2026, 16:39.

Change

Previous filing in this sequence was filed on 22 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001749623 Primary reporting owner

McKenna Mark C.

Relationship: Director
Address: C/O APOGEE THERAPEUTICS, INC., 1 LETTERMAN DRIVE, BUILDING B, SAN FRANCISCO
Signature: /s/ Matthew Batters, as attorney-in-fact for Mark McKenna
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APGE transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -20,000
Change %: -100%
Price
Shares after: 0
Date: 03 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APGE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -150,000
Change %: -100%
Price
Shares after: 0
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $23.60
Footnotes: F2, F3

APGE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -10,370
Change %: -100%
Price
Shares after: 0
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,370
Exercise price: $43.85
Footnotes: F2, F3

APGE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -14,461
Change %: -100%
Price
Shares after: 0
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,461
Exercise price: $41.66
Footnotes: F2, F3

APGE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -7,657
Change %: -100%
Price
Shares after: 0
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,657
Exercise price: $85.00
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Mark C. McKenna is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.

Footnote F2

The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.

Footnote F3

Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.